Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00278993
First received: January 17, 2006
Last updated: June 30, 2014
Last verified: April 2012

January 17, 2006
June 30, 2014
January 2006
January 2008   (final data collection date for primary outcome measure)
Objective Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Bubley Criteria: Patients must have progressive disease to enter study. For outcomes, PSA response must show at least 50% decrease. Duration of response is the time from >50% decrease from baseline to when there is a 50% decrease in nadir. PSA progressive disease- 25% increase from baseline or increase of 5 ng/mL along with measureable disease Stable disease- decline of less than 50% and not more than 25% increase.
  • -- Progression Free Survival (PFS)
  • -- Duration of tumor response
  • -- Objective PSA response rate
  • -- Duration of PSA response
  • -- Tumor related symptom assessment measured by VAS, analgesic consumption, ECOG performance status, and weight change
  • -- Overall tumor response rates (if measurable disease)
Complete list of historical versions of study NCT00278993 on ClinicalTrials.gov Archive Site
  • Duration of Prostate Specific Antigen Response Based on Bubley Criteria [ Time Frame: 12 months. ] [ Designated as safety issue: No ]
    Duration of response is the time from >50% decrease from baseline to when there is a 50% decrease in nadir.
  • Progression Free Survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    From the date study treatment was initiated until the earliest date of the first PSA assessment that determined progressive disease, or the death of death if death occurred without disease progression.
  • Overall Survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Best Objective Tumor Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Based on Response Evaluation Criteria in Solid Tumors (RECIST), consisting of complete response (CR) plus partial response (PR). Defined as the best response from the start of treatment until disease progression or recurrence. Lesions measured by computed tomography (CT) scan and magnetic resonance imaging (MRI). Objective response rate: complete response (CR-disappearance of all lesions)+ partial response (PR-30% decrease in lesion diameter), Progressive Disease (PD-20% increase in lesion diameter), stable disease (SD-neither shrinkage nor increase of lesions).
  • Adverse Events, laboratory parameters, concomitant medications, study drug exposure, physical examination, ECGs.
  • Pharmacogenomic analysis to explore the relationship between the expression of different isoforms of beta-tubulin and/or relevant genes, and sensitivity to E7389 (if possible).
Not Provided
Not Provided
 
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
A Phase II, Multicenter, Open Label, Two Stage Design Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

This is a multi-centre, phase II, open-label, two-stage design, single-arm study in patients with hormone-refractory prostate cancer (HRPC) with advanced (rising PSA) and/or metastatic disease and who have had prior anti-androgen therapy. The study will further explore the efficacy of E7389 by enrollment of patients into two strata: those who have had no prior systemic chemotherapy for their disease (except for mitoxantrone and estramustine), and those who failed no more than one previous chemotherapeutic regimen with tubulin-binding agents such as docetaxel.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
Drug: E7389
Intravenous 1.4 mg/m2 on a 3-week course.
Active Comparator: 1
With stratification
Intervention: Drug: E7389
de Liaño AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
108
January 2008
January 2008   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Males with histologically proven adenocarcinoma of the prostate that has progressed (ie. a minimum of 3 consecutive rises in Prostate Specific Antigen (PSA) (with the last value ≥ 4 ng/mL) taken at least 1 week apart prior to study entry) despite castration or maintenance of castrate-level testosterone (defined as serum testosterone ≤ .50 ng/dL or 1.7 nmol/L), or progressed during non-hormonal chemotherapy.

    Note: Patients previously treated with an antiandrogen must have disease progression documented after antiandrogen withdrawal. Those who have not undergone orchiectomy must continue medical castration with a gonadotropin-releasing hormone analog. At least 4 weeks must have elapsed between the withdrawal of antiandrogens (6 weeks in the case of nilutamide or bicalutamide and four weeks in the case of flutamide or other secondary hormonal therapy) and enrollment, so as to avoid the possibility of confounding results of the response due to antiandrogen withdrawal.

  2. Patients must fulfill one of the following two criteria to be stratified:

    • No prior chemotherapy (except mitoxantrone or estramustine) for advanced and/or metastatic disease as defined in inclusion criteria #1.
    • Failure of no more than one previous chemotherapeutic regimen with tubulin binding agents such as docetaxel.
  3. Resolution of all chemotherapy or radiation-related toxicities to less than grade 2 severity, except neuropathy and alopecia
  4. Age ≥ 18 years.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
  6. Life expectancy of ≥ 3 months.
  7. Adequate renal function as evidenced by serum creatinine ≤ 1.5 times upper limits of normal (ULN) or calculated creatinine clearance ≥ 40 mL/minute (min) per the Cockcroft and Gault formula.
  8. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, hemoglobin ≥ 9.0 g/dL (or 5.5 mmol/L), and platelet count ≥ 100 x 10^9/L. Adequate liver function as evidenced by bilirubin ≤ 1.5 x ULN, alanine transaminase (ALT), and aspartate transaminase (AST) ≤ 3 x ULN (in the case of liver metastases ≤ 5 x ULN).
  9. Patients willing and able to complete the VAS (Visual Analog Scale).
  10. Patients willing and able to comply with the study protocol for the duration of the study.
  11. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion criteria:

  1. Patients who have received chemotherapy, radiation, or experimental therapy within 4 weeks of start of E7389 treatment
  2. Radiation therapy encompassing ≥30% of marrow or treatment with radioactive strontium
  3. Patients who require therapeutic anti-coagulant therapy with warfarin or related compounds; (mini dose warfarin or related compounds are permitted).
  4. Severe / uncontrolled intercurrent illness/infection.
  5. Significant cardiovascular impairment (history of congestive heart failure > NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)
  6. Patients with organ allografts.
  7. Patients with known immunosuppression such as positive HIV status.
  8. Patients who have had a prior malignancy, other than nonmelanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated ≥ 5 years previously with no subsequent evidence of recurrence.
  9. Patients with pre-existing neuropathy > Grade 2
  10. Patients with brain or subdural metastases are not eligible, except if they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least two weeks before starting treatment with E7389.
  11. Patients with meningeal carcinomatosis.
  12. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.
  13. Patients who participated in a prior E7389 clinical trial.
  14. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00278993
E7389-G000-204, 2005-004271-37
Not Provided
Eisai Inc.
Eisai Inc.
Not Provided
Study Director: Asha Das Eisai Inc.
Eisai Inc.
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP